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Objective:Widespread application of computed tomographic scans has increased detection of asymptomatic pul-
monary nodules. A dedicated clinic was established to encourage referral and manage large numbers of patients
with such nodules.
Methods: Patients were evaluated periodically by a nurse practitioner with surgeon oversight, and follow-up im-
aging was centralized. Patients were rescanned at intervals on the basis of radiologist recommendation.
Results:A total of 414 patients, 189 male and 225 female with a median age of 60.2 years (20.7–84.1 years), were
evaluated since April 2000. Median follow-up was 1.51 years (0–6.65 years). Thirty-seven percent (153/414)
were older than 60 years with at least 10 pack-years of tobacco use, whereas 30% (123/414) had never smoked.
A total of 286 patients completed at least 2 years of follow-up computed tomographic evaluation. After 2 years,
24.2% (69/286) were deemed in stable condition and were discharged from further follow-up, whereas 22.4%
(64/286) of patients were followed up longer than 2 years owing to the development of new nodules. Forty-
five percent (127/286) of patients did not complete their recommended follow-up at our clinic. Overall, 3%
(13/414) of our patients have been shown to have a malignant tumor. Only 5 patients underwent curative resection
of a primary lung cancer.
Conclusion: In a population of patients with indeterminate nodules in routine clinical practice, few patients re-
quired intervention and few cancers were detected. Although the benefits of a ‘‘nodule’’ clinic may include pa-
tient reassurance and convenience to referring physicians, a significant number of patients did not complete their
follow-up in our clinic.The widespread application of computed tomography (CT)
scan technology has increased the detection of otherwise
asymptomatic lung nodules. Unfortunately, there is no con-
sensus as to the optimal strategy to evaluate and follow up
these radiologic abnormalities. Both the Fleischner Society
and the American College of Chest Physicians (ACCP)
have offered guidelines as to the follow-up and frequency
of repeat imaging studies, but they are not in complete agree-
ment.1,2 Furthermore, in a controversial recommendation,
the ACCP has recommended against the use of CT scan to
screen individuals at risk for lung cancer except in the con-
text of a clinical trial. For patients with existing nodules, the
ACCP has offered guidelines as to the use of adjunct studies
such as fluorodeoxyglucose positron emission tomography
(FDG–PET), as well as imaging and invasive procedures
for tissue diagnosis based on the pretest probability of
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ACCP use 2-year stability as a suggestion for a benign etiol-
ogy of a pulmonary lesion.
In an effort to evaluate the growing population of patients
with chest radiographic and CT abnormalities, we imple-
mented a clinic dedicated to these patients. This study re-
ports the outcomes of our clinic since its inception in April
of 2000.
METHODS
This study is a retrospective review of patients referred to our clinic for
the evaluation of chest CT abnormalities—most commonly, asymptomatic
pulmonary nodules. Patients were directly referred to the nodule clinic by
any referring physician. No specific guidelines or restrictions were given
for patient referral, but the intention of the clinic was to centralize manage-
ment of surveillance of small and indeterminate lung nodules detected on
studies performed at our home institution and elsewhere. The original
name for this service was the ‘‘SPIN clinic,’’ an acronym for ‘‘Surveillance
of Pulmonary Indeterminate Nodule.’’ It was not anticipated that patients
with highly suspicious lung lesions typical for cancer would be referred
via this mechanism. All patients were initially evaluated by both a nurse
practitioner and a thoracic surgeon. If the patient was believed to be a can-
didate for imaging follow-up, the patient was identified as being eligible for
enrollment in the Surveillance of Pulmonary Indeterminate Nodule Clinic.
If the lesion was considered to be highly suspicious for cancer on evaluation
by the surgeon, the patient was not deemed eligible for inclusion in our sur-
veillance clinic. Follow-up was arranged with a nurse practitioner dedicated
to the clinic with continued oversight by the thoracic surgeon. Dedicated
chest radiologists supervised and interpreted all follow-up CT studies.
These studies were performed without intravenous contrast, using a lowery c January 2009




ACCP ¼ American College of Chest Physicians
CT ¼ computed tomography
ELCAP ¼ Early Lung Cancer Action Program
FDG–PET ¼ fluorodeoxyglucose positron
emission tomography
radiation dose technique with an effective tube current of 30 mA, which is
approximately 3 to 4 times lower than used for CT scans performed for clin-
ical diagnostic purposes at our institution.
For inclusion in this study, all patients must have presented with an initial
chest CT scan. For patients presenting with more than one nodule, we iden-
tified, for the purposes of this review, the nodule on the initial scan and first
follow-up scan having features most concerning for malignancy as the ‘‘in-
dex’’ nodule and tracked the changes of this nodule on subsequent scans.
Follow-up recommendations were based on clinical evaluation and CT
findings. Follow-up appointments were made for the patient at the end of
each clinic visit, and a letter was sent to the referring physician detailing
our recommendations. The patient would receive a telephone call before
the next scheduled visit as a reminder. Follow-up and outcomes were deter-
mined by review of clinic notes and imaging studies. The conduct of this
study was approved by the Washington University School of Medicine Hu-
man Research Protection Office.
Categorical data are expressed as counts and proportions. Descriptive
statistics are expressed as mean  standard deviation and median (range)
unless otherwise specified. Comparisons are done with independent sam-
ples t tests for means of normally distributed continuous variables, and
Fisher’s exact test was used to analyze differences among the categorical
data. All data analysis was performed with SPSS software (SPSS 11.0 for
Windows; SPSS Inc, Chicago, Ill).
RESULTS
A total of 414 patients, 189 male and 225 female with
a median age of 60.2 years (20.7–84.1 years), were evalu-
ated since April 2000. The initial CT scan of the chest that
led to referral for this service was obtained because of an ab-
normal chest x-ray film in 20.3% (84/414), enrollment in the
National Lung Screening Trial (http://www.cancer.gov/
NLST) in 27.3% (113/414), incidental findings on CT scans
done for other reasons in 51.4% (123/414), and direct pa-
tient referral or primary care physician order in 1% (4/414).
Whereas 30% (123/414) of our patients were never
smokers, the remainder were former (40%; 166/414) or ac-
tive smokers (30%; 125/414). Of these former and active
smokers, 92% (269/291) had more than a 10 pack-year
smoking history. Ten percent (38/414) of patients in our se-
ries presented with a diagnosis of chronic obstructive pulmo-
nary disease.
Only a minority of patients in our cohort had a single CT
abnormality. Review of the first follow-up CT scan done on
admission to our clinic revealed resolution of the CT abnor-
mality in 4% (16/414), 1 nodule in 23% (97/414), 2 nodules
in 16% (67/414), and more than 2 nodules in 50% (206/
414) of patients. In the remaining 28 patients, no data are
available as 6 patients were discharged from the clinic with-The Journal of Thoracic andout further follow-up, 6 are awaiting their first follow-up
scan, 9 patients declined further follow-up in our clinic or
chose to continue their care with their referring physician,
1 patient died before follow-up, and the remaining 6 patients
were lost to follow-up.
The median initial nodule size was 0.6 cm (0.2–4.3 cm).
Seven patients in our series presented with masses greater
than 3 cm in size. On review of the clinical notes and radiol-
ogy reports, the cause of these largest lesions was attributed
to infectious etiology in 4 of 7, and 1 patient was given a di-
agnosis of silicosis of the lung. In 1 patient the mass demon-
strated a benign pattern of calcification, and in the remaining
patient ground-glass opacity requiring further evaluation
was noted.
Median follow-up was 1.51 years (0–6.65 years). At least
1111 CT scans were performed in the entire cohort of pa-
tients. A total of 286 patients received their initial scan at
least 2 years before the preparation of this report and would
therefore have been eligible for discharge on the basis of CT
stability. Of these eligible patients, only 55% (159/286)
completed 2 years of clinic follow-up. Forty-five percent
(127/286) of patients did not return for all of the scheduled
follow-up visits. After at least 2 years, 24.2% (69/286)
were deemed in stable condition on CT and were discontin-
ued from further follow-up. Despite stability of the index
nodule, 22.4% (64/286) of patients were followed up longer
than 2 years owing to the development of new nodules. Of
the remaining 26 patients who completed 2 years of fol-
low-up, 2 were discharged after further imaging studies,
17 patients continued to be observed, and 7 patients were
lost to follow-up. In the patients who had completed at least
2 years of follow-up, the mean number of scans was 4, with
a time interval between CT scans of 266 days.
Forty-two (10.1%) of 414 patients underwent FDG–PET
imaging, which suggested malignancy in 8 of the 42 scanned
patients. Measurements of standardized uptake value were
not uniformly reported by the radiologists and therefore
not reportable here. In 67% (28/42) of PET-screened pa-
tients, the PET imaging was used within the first two clinic
visits. However, FDG–PET was not consistently used before
invasive procedures for tissue diagnosis in all patients. Of
the 20 patients undergoing an invasive procedure for patho-
logic diagnosis, 11 had preliminary FDG–PET imaging and
9 went directly to biopsy or resection without FDG–PET.
A pathologic diagnosis was made by CT-guided fine-nee-
dle aspiration in 3 patients and by operative procedure in 17
patients. Seven (7/20) of the patients having a biopsy under-
went a surgical procedure for what turned out to be a diagno-
sis of an infectious or inflammatory process. In 3 patients
with a benign diagnosis, a thoracotomy was required to ob-
tain tissue diagnosis. Overall, 3% (13/414) of our patients
have been proven to have cancer. Nine patients had non–
small cell lung cancer, 1 patient had small cell lung cancer,
1 patient had lymphoma, and 2 patients had lung metastasisCardiovascular Surgery c Volume 137, Number 1 31
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went a biopsy procedure owing to change in the nodule
from baseline size and appearance on follow-up CT scan.
There was considerable variability in the length of follow-
up before pathologic diagnosis. Forty-six percent of patients
(6/13) were followed up by radiologic imaging for at least 2
years before the diagnosis of a cancerous lesion. In 9 of 13
patients with cancer, at least 4 follow-up scans were ob-
tained before the diagnosis of malignancy, and in 2 patients,
tissue diagnosis was obtained after 8 follow-up CT scans. In
those patients followed up for more than 2 years, the index
nodule began as a lesion 1 cm or less in size and was often
accompanied by multiple other small nodules. Development
of new small subcentimeter lesions in these cases prompted
continuation of CT surveillance beyond the 2-year period
originally intended for the index nodule.
Among the 10 patients with lung cancer, the median age
was 64 years (58.0–78.0 years) with a mean smoking history
of 57.3  30.8 pack-years. There was no difference in
age (P ¼ .173), gender (P ¼ .406), or smoking history
(P ¼ .063) between these 10 patients diagnosed with
primary lung cancer and the entire cohort. The patient with
a diagnosis of small cell lung cancer did not undergo surgical
resection but was offered chemotherapy and radiation. Of
the 9 patients with non–small cell lung cancer, 1 patient
was not offered surgery owing to discovery of asymptomatic
metastatic disease and 1 patient underwent thoracotomy
only to discover extensive multistation N2 disease resulting
in wedge resection and lymph node sampling being per-
formed. Two patients believed not to be operative candidates
owing to poor pulmonary function were treated with stereo-
tactic radiation, and the remaining 5 patients underwent re-
section of node-negative lung cancer (3 patients with T1
N0, 1 patient with T2 N0, and 1 patient with T4 N0).
DISCUSSION
Our clinic was designed to facilitate the follow-up and
evaluation of patients with pulmonary indeterminate nod-
ules. The original intent was to provide a streamlined service
for our patients and their referring physicians. This report is
a retrospective review of our experience. Although we are
unable to offer conclusions as to the rationale and utility
of current recommendations for the imaging evaluation
and clinical testing of patients with indeterminate pulmonary
nodules, we are able to provide an overview of the experi-
ence of a busy thoracic surgery service at a large tertiary re-
ferral hospital in the United States.
Both the Fleischner Society and the ACCP recommend 2
years of surveillance to deem a lesion stable.1,2 Using the 2
years of imaging follow-up as the benchmark for discharge
from our clinic, surprisingly few patients met the criterion.
We do not have data on why patients did not follow up in
our clinic over the recommended 2-year period. We did con-
tact a subset (n ¼ 16) of patients who did not return for the32 The Journal of Thoracic and Cardiovascular Surgfirst recommended follow-up. Of these 16 patients, 1 died of
unrelated illness, 9 declined further follow-up in our clinic
and chose to continue care with their referring physician, 1
patient declined follow-up owing to his own opinion that
the nodules were not a health care issue, 1 patient had insur-
ance deny further follow-up at our center, and the remaining
4 were unable to be contacted. We speculate that a significant
reason for patient attrition may be the wide region of referral
to our center. After reassurance from the initial visits that no
immediate surgical intervention was needed, patients may
have elected to follow up with their own local physicians
owing to the difficulties associated with prolonged travel
times to our clinic. At the implementation of this clinic,
we did not undertake any formal assessment to study the
psychosocial impact of patients being evaluated in a clinic
dedicated to chest CT abnormalities. However, from patient
and family interaction, it is clear that many patients find re-
assurance from periodic evaluation by a thoracic surgeon for
their CT abnormalities. Referring physicians were also kept
continually informed of the progress of their patients and our
decision-making process, facilitating long-term care by the
referring physician.
Of the patients eligible for 2 years of follow-up, 22.4%
had a new nodule develop, leading to recommendation for
further imaging. The development of new nodules is ex-
pected in patients with smoking history. In the Early Lung
Cancer Action Program (ELCAP) study, 23% of patients
had a nodule on the initial screening, and an additional
5% had a new nodule develop during the follow-up period.3
The highest prevalence of lung cancer reported in any trial of
CT scanning has been the 2.7% reported by the ELCAP in-
vestigators.4 The variability of tumor doubling times further
affects recommendations for duration of follow-up. At pre-
sentation, a very small nodule may take considerably longer
to become clinically relevant than a larger nodule with the
same doubling time. Given the lengthy time interval from
initial presentation to pathologic diagnosis demonstrated in
our series, it is unclear what implication this has for the nu-
merous other patients who were discharged from our clinic
because of stable imaging findings with 2 years of follow-
up. A longer period of follow-up may be necessary.
In another large prospective study of the role of CT screen-
ing studies, investigators at the Mayo Clinic reported that 847
new nodules were detected in their cohort of 1520 patients
followed up for 5 years with annual CT scan.5 In fact, 56%
of patients presented with a malignancy not found on the ini-
tial CT scan.5 The development of new indeterminate nod-
ules raises the question of when to stop screening patients.
Given the lack of compelling data, we would not offer contin-
ued screening CT scans outside the setting of a clinical trial.
Few patients required surgical intervention. From our
clinic’s evaluation process, 3 patients were referred to the ra-
diology service for CT-guided biopsy, and 17 operative pro-
cedures were performed. Of these procedures, the majorityery c January 2009
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mies were performed for what was ultimately deemed a be-
nign process. Participation in our clinic, with early
involvement of a thoracic surgeon, may have prevented un-
necessary procedures. Whereas 5% (20/414) of patients in
our series underwent a diagnostic procedure, the Interna-
tional Early Lung Cancer Action Program Investigators
reported nearly double the rate of diagnostic procedures—
9.4% (535/5646 patients with nodules).3
We were able to identify 10 patients with primary lung
cancer. Unfortunately, only 5 patients underwent curative re-
section. Early detection and frequent follow-up did not lead to
curative resection in the other 5 patients. In fact, 3 of the 5 pa-
tients who underwent curative resection required more than 2
years of follow-up before a clinical decision was made to per-
form a procedure for tissue diagnosis. The need for prolonged
follow-up was not due to change in the initial index lesion,
but to the development of new subcentimeter lesions, with
subsequent recommendations for continued follow-up.
The management and follow-up of patients with asy-
mptomatic pulmonary nodules remains an important and
challenging clinical problem. Although a number of profes-
sional societies provide recommendations to guide the care
of these patients, our experience with this group of patients
has not been straightforward. We were not able to centralize
the care of these patients at our institution, and close to half
of patients enrolled in our clinic did not complete 2 years of
follow-up at our center. Well over 1000 CT scans were
performed at our center in a cohort of 414 patients. Whereas
a diagnosis of primary lung cancer was made in 10 patients,
only 5 of these patients could be definitively treated with
surgery. At the time of this report, our formal clinic for
the evaluation and follow-up of patients with indeterminate
nodules has been disbanded owing to cutbacks in advanced
nurse practitioner personnel. We believe that further
prospective investigation is required to evaluate the optimal
treatment strategy for patients with indeterminate pulmo-
nary nodules and to determine the long-term benefits of
early detection.
We are grateful for the efforts of Dr Joel Cooper for the design
and inception of this clinic.
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Discussion
Dr Joel D. Cooper (Philadelphia, Pa). I think you have proba-
bly disclosed conflict, which I was going to disclose, having been
involved in setting this up. I have no financial conflict. Ego is an-
other matter. [Laughter.]
Dr Veeramachaneni, it was a very good presentation, providing
a lot of very useful information. Perhaps I can summarize, as you
did, and add a little bit more.
Why does a surgeon want to get involved with ditzels, with little
nodules? As you pointed out, it certainly is a way of alleviating anx-
iety on the part of the patient and providing a service to the patient
and the primary physician, both of whom have received letters from
the radiologist saying, ‘‘You have a nodule. It could be lung cancer.
You should be followed up.’’ And who better to follow it up than
a surgeon, ideally a conservative surgeon, who is in the best posi-
tion to make a judgment as to what should be watched and what
should be excised? By the way, I think it does promulgate the inter-
est of thoracic surgeons in all things relating to lung cancer. I have
often been quoted as saying nothing is too small, in my opinion, for
a thoracic surgeon to be involved in.
I think it also fosters research into the early diagnosis: how to
tell which nodules are cancer or not. It not only maintains the ra-
diologic skills of the thoracic surgeons, but also encourages other
investigators to use this as a population base to figure out some
tag, some marker, some immunologic way of determining if a nod-
ule is malignant. Here you have a database, a group of patients
who are being followed up. I think that is another potential envi-
ronment.
I think it supports the minimally invasive treatment of early can-
cers, whether by ablative techniques or excisional techniques.
Again, I think it is not bad for the thoracic surgeon to be involved.
We started a clinic in Philadelphia. We talked to the HMO that
did not send their patients to our institution for CT scans. I said, ‘‘I
will not take the responsibility of following the patients and saving
you a lot of money and unnecessary surgery unless you agree to al-
low us out of network to do the CT scans,’’ and they said yes.
My final question concerns the loss of follow-up of patients.
Have you any idea as to whether it was because of the patient or
because of insurance issues, and do you have any follow-up on
those patients to know what the ultimate outcome was?
Dr Veeramachaneni. We lost 45% of our patients to follow-up,
and we were not able to contact all of them individually to deter-
mine why they did not follow up. All that we do have is a clinic
note that indicates that they were scheduled for follow-up and
they did not show up. A small subset of patients showed up for their
first clinic visit where the surgeon as well as the nurse practitioner
evaluated them. They were subsequently scheduled for follow-up.
About 20-odd patients in that group failed to show up for their first
follow-up. Those patients we have contacted. Approximately half
of them chose to continue follow-up with their referring physician
and the other half just chose to discontinue follow-up entirely. I do
not have a good sense of whether it was an insurance or financial-
driven thing, but given the large catchment area of WashingtonCardiovascular Surgery c Volume 137, Number 1 33
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sible.
Dr Cooper. I noticed that you had a very low incidence in the
use of PET scans, which I greatly applaud. I think their value is un-
certain for the 3-, 4-, 5-, and 6-mm nodule. The standard seems to
be that everybody gets a PET scan, and if they have a positive one,
they are told they have cancer. I certainly think that your limited use
of PET scan saved a lot of money for the system. Do you have any
comment as to what you believe the importance of PET scan is in
monitoring these patients?
DrVeeramachaneni. For this presentation, I did not actually in-
clude that information, but we had 42 patients out of the entire
cohort, or approximately 10%, who underwent PET imaging. It
suggested malignancy in 8 patients, but its accuracy was not
100%, because most of these lesions were in the 1-cm or perhaps
even smaller category.
Dr Cooper. Actually, we have only gotten started. We are fol-
lowing up about 130 patients. Six people came in with lung cancers
that were pretty obvious. It is surprising how many patients are out
there who have been followed up for lesions that even the conser-
vative individual would not normally follow. Maybe that is a sec-
ondary benefit.
My last question is this: You mentioned 2 patients who either
had widespread metastases or N2 disease when they were finally
discovered to have cancer. That is somewhat different from Claudia
Henschke’s experience. I know she has been subject to a lot of crit-
icism, but what she did demonstrate is that careful follow-up using
different types of tools for early nodules can lead to a resection of
those that are cancer, an extremely high cure rate, and a very low
incidence of unnecessary operative interventions. Have you any
messages for us on how to avoid following up patients and subse-
quently finding out that they have N2 or widespread disease? Do
you think in retrospect there is anything different that you would
have done?
DrVeeramachaneni. In 1 of those 2 patients the nodule in ques-
tion was in the setting of an apical scar. The patient was followed up
for a number of years, and there was some controversy as to
whether there was any radiographic change. In fact, this case was
actually presented at a multidisciplinary conference and the deci-
sion was made to offer the patient just another follow-up imaging
study in a 6-month interval. In the meantime, however, bone metas-
tasis developed. In the other patient, who presented with T1 N2 dis-
ease, the PET scan was also negative. I apologize that we do not
have standardized uptake value measurements of that patient be-
cause none were reported at that time, but micrometastatic disease
was noted at the time of thoracotomy.
Dr Cooper. Thank you very much, Dr Veeramachaneni. It was
a great paper.
DrRossM. Bremner (Phoenix, Ariz). I think one of the benefits
of having a clinic like this is to allow for easy referral for physicians
who do not know what to do with a pulmonary nodule. It may be
very obvious to us that it is a lung cancer. To allow that ease is
a great benefit of having such a clinic.
I have two quick questions. Do you have any information on the
cost-efficacy per patient who ended up being treated for cancer for
those 1000-plus scans that you did? Second, how did you address
the malpractice issues involved with this, the patients who do not
get followed up and then the patients whom you stop following34 The Journal of Thoracic and Cardiovascular Surgup after 2 years, who may have an indolent cancer or bronchioloal-
veolar carcinoma lesion.
Dr Veeramachaneni. I cannot comment on cost analysis. I do
not know the exact data as to how much revenue was generated
or the cost. That is somewhat of a soft number, as I have discovered
in terms of trying to figure out the exact cost of anything.
As to your second question, at the time that each patient is seen
in clinic, we recommend follow-up and we also schedule their fol-
low-up for their next visit. In addition, we inform the referring pri-
mary care physician of the need for follow-up and what our findings
were in the form of a letter. However, we have not tried to track
down those patients who do not show up subsequently.
Dr Scott J. Swanson (New York, NY). I enjoyed this. I think it is
a great addition to what we do as thoracic surgeons.
It seems to me you may want to rethink the 2-year strategy, since
over half of your patients presented after 2 years. What is your cur-
rent recommendation about how long to follow up patients? Did
you try to recontact the people that you dismissed after 2 years to
see how they are doing?
Dr Veeramachaneni. I completely agree with you that the
2-year benchmark was established in an era before high-resolution
CT scans and finding patients with these small nodules. Just as the
ELCAP trial demonstrated, we might be diagnosing these patients
at an earlier stage of cancer, but it is still a matter of debate as to
whether we are accomplishing improved morbidity or mortality
by acting on these data. Once we have identified patients with
a nodule, I think we are somewhat obligated to continue to counsel
these patients and follow them. We do not have a specific end
point.
As to the question of what do we do about the patients who were
dismissed from our clinic, all of these patients did have radio-
graphic stability and they did not have new nodules that would
have mandated further testing. If these individuals are considered
at high risk, their physicians might want to enroll them in a screen-
ing trial. However, right now I do not think there are any data to
support enrolling high-risk patients routinely into screening pro-
grams outside of a clinical trial.
Dr Frank C. Detterbeck (New Haven, Conn). The spectrum of
disease that we are seeing is changing dramatically. I recently did
a review of this. Tumor doubling time for normal, routine-care–
detected patients is 136 days on average, and in CT screening stud-
ies it is 485 days, dramatically different. That is why the whole
2-year mark is changing. It is clear that we are seeing indolent tu-
mors in a different spectrum of disease.
My question is really something to work on. I think that you
would be in an ideal situation to look at patients who were discov-
ered as part of a CT screening trial and those patients who happened
to be walking down the street within 100 yards of an emergency
room and somehow ended up with a scan and see if those are similar
populations. I suspect they are, but it would be very useful.
Dr Veeramachaneni. Thank you.
Dr Walter Klepetko (Vienna, Austria). How many of your
patients had a history of any other malignant disease? Did you ex-
clude those patients from such a study? Would it have any impact
on your follow-up strategy?
Dr Veeramachaneni. We did not exclude any patients who
were referred to our clinic. The 2 patients who received a diagnosis
of metastatic lesions in fact had a known history of nonlungery c January 2009
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colorectal cancer. In terms of clinical management and follow-up of
those nodules, it was left to the discretion of the surgeon evaluating
that patient whether it should be 6-month interval follow-up or 1-
year follow-up.
Dr Klepetko. My second question concerns your judgment of
changes in the size of the nodules. Was it done with the naked
eye of the radiologist or did you apply volumetric assessment?
Dr Veeramachaneni. I do not know the specific technique used
by our radiologists, but from my recent exposure to our radiolo-
gists, I do not believe they use an automated volumetric assessment.
They rely on the measurements that they routinely take. I should
stress that it is the same group of radiologists, the same CT scanner,
and, no doubt, the same technique.
Dr Cerfolio. How many people in the audience are using volu-
metric measurements for these ditzelomas with thin-cut CTs as op-
posed to just linear?
[A show of hands.]
Dr Cerfolio. That is what we have gone to at the University of
Alabama at Birmingham. I think that is a more accurate way. If they
have only one nodule, you can get them in and they get a thin slice,
they get less radiation, and they do not need intravenous contrast.
DrKlepetko. It is extremely helpful and provides very objective
data.
Dr Cerfolio. And it is more accurate.
Dr John R. Benfield (Los Angeles, Calif). A number of years
ago I reviewed a paper that was subsequently published in the An-
nals of Thoracic Surgery, which indicated that there is perhaps little
need, if any, for surgeons to follow up their patients postoperativelyThe Journal of Thoracic andlong term. I wrote an invited, or perhaps not so invited, commentary
speaking against that and in favor of surgeons following up their
patients. What is your posture toward following up patients postop-
eratively long term? Do you agree or disagree with the thesis that
long-term postoperative follow-up can simply be relegated to pri-
mary physicians or referring physicians?
Dr Veeramachaneni. I think as surgical oncologists and tho-
racic oncologists, we have an obligation to continue to follow up
these patients, and that is certainly the practice at Washington Uni-
versity.
Dr Erino Angelo Rendina (Rome, Italy). My question echoes
that of Dr Benfield. As a matter of fact, I think your paper is of ex-
treme interest from a speculative point of view. However, from the
standpoint of manpower, is it really indispensable that thoracic sur-
geons be involved in such a clinic, considering that in the time span
of 2 years, only 5 patients were operated on out of more than 400?
Dr Veeramachaneni. In the interest of full disclosure, I should
state that this clinic is formally disbanded owing to lack of nurse
practitioner personnel. This happened within the past year, but
these patients continue to be seen in the regular clinic. The way
the clinic was designed, a nurse practitioner who was following
up these solitary pulmonary nodule patients would show up at
the same time as the regular clinic. These patients would be sched-
uled at the same time as the regular clinic, but most of the patient
education follow-up would be done by the nurse practitioner. The
surgeon would be able to come in and say hello or provide
additional counseling, but the whole idea was to unburden the sur-
geon from routine follow-up while at the same time providing high-
quality care.Cardiovascular Surgery c Volume 137, Number 1 35
